The Medibank share price has leapt 5% in a month. Could it be on the comeback trail in May?

A young basketballer in a wheelchair throws his arms up in triumph.A young basketballer in a wheelchair throws his arms up in triumph.

The Medibank Private Ltd (ASX: MPL) share price has risen by around 5% over the past month. But can the leading private health insurer’s shares keep going up?

Medibank has materially outperformed the S&P/ASX 200 Index (ASX: XJO), which has fallen by around 3% over the last month.

This week, the company gave a presentation at the Macquarie Australia conference and provided an update on its outlook for FY22.

Medibank presentation

The company says that private health insurance participation growth remains “strong”.

It notes there has been a shift in customer attitudes towards private health insurance. And by the direction of the Medibank share price, it appears to be a positive one.

Medibank says that private health insurance is an improving proposition given concerns about public hospital wait times. Further, it is reportedly seen as “more affordable and better value”, and consumers continue to invest in their health and wellbeing.

The ASX share points to six consecutive quarters of industry policyholder growth. The rolling 12-month policyholder growth increased from 2.68% in September 2021 to 2.79% in December 2021.

‘New to industry’ and younger cohorts are “major contributors” to policyholder growth, which Medibank says are positive signs for industry sustainability. There has also been a “significant” improvement in policyholder lapses.

Outlook for the private health insurer

For those interested in the Medibank share price, here’s what the company expects in the coming months.

Medibank says it expects industry participation growth to be higher than pre-pandemic levels over the medium term.

Growth will be supported by population growth, continuing shifts in consumer attitudes towards health and “strong bipartisan support” for the role of private health.

However, Medibank says that affordability is still key for growth. It has deferred its April 2022 premium increase of 3.1% for six months.

The ASX share says it’s on track to achieve resident policyholder growth of between 3.1% to 3.3% in FY22. It also continues to gain market share, which increased to 27.36% as at 31 December 2021. This was a rise of 14 basis points over the 2021 calendar year.

As at 30 April 2022, the financial year-to-date resident policyholder growth was 2.3%.

The company sees further growth opportunities. Target markets include corporate and regional customers. It thinks it can improve retention, particularly in its AHM business. It points to productivity and cost discipline, which can provide opportunities to invest for growth.

The ASX share is also targeting ‘inorganic’ growth.

The underlying average net claims expense per policy unit is forecast to be around 2.3% among resident policyholders in FY22.

Finally, the FY22 health insurance management expenses are expected to be around $530 million. The FY22 productivity target of $15 million in health insurance management expenses is “on track”.

Medibank share price targets

Two of the recent ratings from brokers have been positive.

Ord Minnett rates the business as ‘accumulate’ with a price target of $3.50, implying an upside of around 10%.

Likewise, Credit Suisse rates Medibank as ‘outperform’, with a price target of $3.50. This broker thinks that the current environment is supportive for Medibank earnings.

On Ord Minnett’s numbers, the Medibank share price is valued at 21x FY22’s estimated earnings with a projected grossed-up dividend yield of 5.3%.

Thus, using Credit Suisse numbers, the Medibank share price is valued at 20x FY22’s estimated earnings with a projected grossed-up dividend yield of 6.25%.

The post The Medibank share price has leapt 5% in a month. Could it be on the comeback trail in May? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Medibank right now?

Before you consider Medibank, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Medibank wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

More reading

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/xsg47mu

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s